[HTML][HTML] Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial
B Namutangula, G Ndeezi, JS Byarugaba, JK Tumwine - Malaria Journal, 2007 - Springer
B Namutangula, G Ndeezi, JS Byarugaba, JK Tumwine
Malaria Journal, 2007•SpringerBackground Several reports have suggested that raised intracranial pressure (ICP) is a
major contributor to death among children with cerebral malaria. Mannitol, an osmotic
diuretic, effectively lowers ICP and is used to treat post-traumatic raised ICP. It is not clear
whether intravenous mannitol given to children with cerebral malaria improves clinical
outcome. The objective of this study was to determine the effect of mannitol as adjunct
therapy on the clinical outcome of children with cerebral malaria. Methods This randomized …
major contributor to death among children with cerebral malaria. Mannitol, an osmotic
diuretic, effectively lowers ICP and is used to treat post-traumatic raised ICP. It is not clear
whether intravenous mannitol given to children with cerebral malaria improves clinical
outcome. The objective of this study was to determine the effect of mannitol as adjunct
therapy on the clinical outcome of children with cerebral malaria. Methods This randomized …
Background
Several reports have suggested that raised intracranial pressure (ICP) is a major contributor to death among children with cerebral malaria. Mannitol, an osmotic diuretic, effectively lowers ICP and is used to treat post-traumatic raised ICP. It is not clear whether intravenous mannitol given to children with cerebral malaria improves clinical outcome. The objective of this study was to determine the effect of mannitol as adjunct therapy on the clinical outcome of children with cerebral malaria.
Methods
This randomized double-blind placebo controlled clinical trial was carried out at the Emergency Paediatric ward of Mulago Hospital, Uganda's national referral and teaching hospital. One hundred and fifty six children aged 6 to 60 months with cerebral malaria were randomized to either one dose of mannitol 1 g/kg or placebo, in addition to intravenous quinine. Main outcome measures included coma recovery time; time to sit unsupported, begin oral intake; duration of hospitalization; death and adverse effects.
Results
Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups. There was no significant difference in the mortality between the placebo (13/80 or 16.3%) and mannitol (10/76 or 13.2%) groups: RR = 1.2 (CI 0.5–2.7). No adverse effects were observed after administration of mannitol.
Conclusion
Mannitol had no significant impact on clinical outcome of cerebral malaria. It is difficult to recommend intravenous mannitol as adjunct therapy for childhood cerebral malaria.
Clinical registration number
ClinicalTrials.gov ID: NCT00113854
Springer
